Small Cell Lung Cancer

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and safety notes.

Experts from Memorial Sloan Kettering Cancer Center discuss updates from the 2026 European Lung Cancer Congress.

New first-line ES-SCLC data show iza-bren plus serplulimab drives 88% responses and manageable safety, setting up phase 3 trials.

Mohamed K. Mohamed, MD, PhD, discusses how CIM disrupts treatment, burdens patients, and why a proactive management approach is critical in SCLC care.

ELCC 2026 spotlights lung cancer breakthroughs—ADCs, EGFR combo sequencing, HER2 TKIs and SCLC bispecifics—reshaping treatment choices.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.

IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

Durvalumab boosts survival in limited-stage SCLC, yet US costs miss value thresholds, fueling urgent debates on access and pricing.

WVU Medicine pioneers nonthermal PEF therapy for metastatic lung nodules, using robotic bronchoscopy to target tumors precisely and potentially boost immune response.

Trilaciclib reshapes SCLC supportive care by protecting bone marrow from chemo, reducing anemia and thrombocytopenia, and improving treatment tolerance and quality of life.

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

South Florida’s diverse lung cancer cases fuel genomic breakthroughs, push screening beyond smokers, and accelerate 2026 targeted-therapy progress.

During a live event, Joshua K. Sabari, MD, discussed subgroup analyses and safety outcomes of the IMforte trial in extensive-stage small cell lung cancer.

Promising interim results highlight the potential of Olvi-Vec in treating advanced lung cancer, showcasing efficacy and safety in challenging patient populations.

During a live event, Joshua K. Sabari, MD, discussed outcomes of the phase 3 IMforte trial in extensive-stage small cell lung cancer.

The FDA has granted a full approval to tarlatamab-dlle for extensive-stage small cell lung cancer.

Small cell lung cancer treatment evolves with groundbreaking therapies, improving survival rates and offering new hope for patients in 2024 and beyond.